According to knowledge of the gut microbiota, the phylogenetic range and characteristics of the
organisms are under investigation as novel therapeutics. (Next-generation probiotics)
As the microbiota studies proceed, single bacterial strains are screened and isolated, aiming to characterize their relationship with the amelioration of specific diseases.
Among these, some of them are expected to emerge as next generation probiotics. Next-generation probiotics are live microorganisms identified based on comparative microbiota analyses that, when administered in adequate amounts, confer a specific health benefit on the host.
Traditional probiotics such as Bifidobacterium spp., Lactobacillus spp. and many others may effect on amelioration of diseases however, their effects are statistically marginal.
On the other hand, the administration of traditional probiotics does not aim against specific diseases. Based on these situations, identification and characterization of novel and disease-specific next-generation probiotics are urgently needed.
